Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Active Deal-Making Year Anticipated In HCV As New, Better Drug Combos Emerge

Executive Summary

Following the European Association for the Study of the Liver's annual meeting this past week in Vienna, Austria, it became clear that most companies active in the hepatitis C space hope to be part of the current best hope for HCV therapy: a once-daily, oral cocktail of antiviral drugs that will replace the current standard of care

You may also be interested in...



Bristol, Pharmasset To Study Oral HCV Regimen Together

Partnership to study Bristol's NS5A inhibitor with Pharmasset's polymerase inhibitor is the first cross-company collaboration to study two oral agents in hepatitis C.

Idenix Clinical Hold On Two Hep C Programs May Be Resolved By Year-End

Serious adverse events that triggered an FDA clinical hold on two of Idenix's hepatitis C programs - IDX184 and IDX320 - could have been caused by an unforeseen effect of combining the drugs, as opposed to a defect with one of the individual drugs

Idenix Clinical Hold On Two Hep C Programs May Be Resolved By Year-End

Serious adverse events that triggered an FDA clinical hold on two of Idenix's hepatitis C programs - IDX184 and IDX320 - could have been caused by an unforeseen effect of combining the drugs, as opposed to a defect with one of the individual drugs

Related Content

Topics

UsernamePublicRestriction

Register

PS052149

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel